Sotrovimab is a medication that has been used to treat COVID-19 on an emergency/interim use basis. It is used by people 12 years of age and older who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 7 days, and are not hospitalized. To receive sotrovimab, you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung, kidney, or heart disease, diabetes). Talk to your doctor about the risks and benefits of treatment with sotrovimab.Sotrovimab is an antibody which, when given soon after infection, can neutralize the coronavirus and may prevent worsening of COVID-19 symptoms. More information about sotrovimab is available from the patient information sheet provided by your health care professional. If you are enrolled in a study, information should be provided by the doctor via the Informed Consent Form.There is limited information about how safe and effective sotrovimab is for treating COVID-19. Study results show that sotrovimab may help people who have recently tested positive for coronavirus stay out of the hospital. Sotrovimab is not for use by people who are hospitalized due to COVID-19, or who need supplemental oxygen or a ventilator due to COVID-19.The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of sotrovimab, and it is always the responsibility of treating practitioners to exercise independent judgment in making care decisions.
How to use Sotrovimab 500 Mg/8 Ml (62.5 Mg/Ml) Intravenous Solution (EUA) SARS-Cov-2 Antibodies - Bamlanivimab:Sotrovimab
Sotrovimab is given one time by injection into a vein by a health care professional. A health care professional will observe you during your infusion and for at least another hour after your treatment in case you have serious side effects.
Tell your doctor if your condition does not get better or if it gets worse.
Pain, soreness, swelling, or bruising at the injection site may occur. If you notice any of these effects, tell your health care professional promptly.
An infusion reaction may occur while this product is being given and up to 24 hours after infusion, causing symptoms such as low or high blood pressure, dizziness, slow/fast/irregular heartbeat, chest pain, trouble breathing, fever, chills, nausea, headache, confusion, sweating, or muscle pain. Get medical help right away if you notice any of these symptoms. A slower rate of infusion may help to lessen the risk of this reaction.
A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
Information is limited and it is unknown at this time if sotrovimab causes other serious side effects. This is not necessarily a complete list of possible side effects.
Contact your doctor for medical advice about side effects.
Before using this medication, tell your doctor if you have any allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems.
Limited information is known at this time about other medical conditions that may affect how sotrovimab works, or if sotrovimab may affect other medical conditions.
Before using this medication, tell your doctor your medical history.
To avoid spreading the virus, you should continue to take precautions such as self-isolation, wearing a mask, social distancing (physical distancing), washing hands, and not sharing personal items.
Tell your doctor if you are pregnant or think you are pregnant. Sotrovimab should be used during pregnancy only if the possible benefits are greater than the possible risks.
It is unknown if sotrovimab passes into breast milk. The risks of breast-feeding while infected with COVID-19 and while using this product should be discussed with the doctor.
Drug interactions may change how medications work or increase your risk for serious side effects. Information is limited and it is unknown at this time if sotrovimab has drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
Overdose information is not available at this time.
Not applicable. This product is not stored at home.
sotrovimab 500 mg/8 mL (62.5 mg/mL) intravenous solution (EUA)Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
Free RX Coupon
Save up to 80% on your prescriptions.
Save up to 80% on your prescription with WebMDRx
Are you currently using Sotrovimab 500 Mg/8 Ml (62.5 Mg/Ml) Intravenous Solution (EUA) SARS-Cov-2 Antibodies - Bamlanivimab:Sotrovimab?
This survey is being conducted by the WebMD marketing sciences department.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.